Tempus AI Inc. stocks have been trading up by 7.95 percent after upbeat coverage of its AI-driven healthcare data platform.
Live Update At 09:18:42 EDT: On Friday, May 29, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 7.95%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Tempus AI (TEM) has been trading like a textbook momentum name. Over the past few weeks, TEM has pushed from the mid‑$40s to a recent close above $51, with a spike to just over $56 earlier in the month. That kind of range tells traders this is a volatile AI‑healthcare story where headlines drive big swings.
On the fundamentals, Tempus AI reported about $1.27B in trailing revenue, with revenue per share near $7.29. Guidance calls for $1.2B in 2025 and roughly $1.59B in 2026, signaling solid top‑line growth. TEM’s price‑to‑sales ratio near 6.2 shows the market is paying a premium for that growth and its AI data platform narrative.
Margins remain negative. EBIT margin sits around ‑17.6%, and profit margin is roughly ‑22.2%, reflecting heavy spend on research, data, and go‑to‑market. But adjusted EBITDA guidance turns positive in 2026, hinting that operating leverage is starting to show up. The balance sheet carries meaningful leverage, with total debt‑to‑equity around 1.4, but current and quick ratios above 3 give Tempus AI a decent liquidity cushion. For active traders, that mix—strong revenue growth, improving profitability metrics, and volatility on the chart—keeps TEM firmly in play.
Why Traders Are Watching Tempus AI Now
Tempus AI is not just another AI buzzword ticker. TEM is inserting its platform deep inside big‑pharma pipelines and day‑to‑day clinical workflows, and that’s exactly what momentum traders look for in a story stock.
The latest move with Bristol Myers Squibb is a clear tell. Tempus AI expanded an existing collaboration so Bristol Myers Squibb can lean on its AI and multimodal real‑world data across five oncology and neuroscience programs. That is not a pilot. Five programs means Tempus AI data and models are helping shape how trials are designed, which patients get enrolled, and how regulators might view the evidence. For TEM, that kind of embedded role often turns into sticky, recurring revenue and a long runway of follow‑on work.
In parallel, Tempus AI is pushing hard into neurology. By adding Quanterix’s LucentAD Complete blood‑based Alzheimer’s biomarker panel into its Tempus Next care‑gap platform and clinical ordering system, TEM moves beyond oncology and deeper into brain health. Neurologists can identify Alzheimer’s candidates and order testing inside existing AI‑driven workflows and EHR integrations. That shrinks friction at the point of care and expands Tempus AI’s footprint every time a doctor clicks “order.”
On the capital side, TEM priced an upsized $400M 0% convertible senior notes deal due 2032. The stock popped more than 1% premarket after pricing, which tells you traders were comfortable with the raise. A 0% coupon gives Tempus AI cheap capital to fund growth while signaling confidence from buyers. Yes, convertibles bring future dilution risk, but the positive reaction shows the market is focused on expansion, not balance‑sheet stress. Combine that with 2025 revenue around $1.2B and 2026 guidance near $1.59B plus positive adjusted EBITDA, and TEM looks like an AI platform shifting from story mode toward scale.
More Breaking News
- AVAV Stock Jumps As U.S. Backs Freedom Eagle-1 Expansion
- ACHR Stock Builds Momentum As Certification Milestones Stack Up
- Micron Stock Rockets As $1 Trillion AI Memory Bet Accelerates
- Ford Stock Surges As Ford Energy Lands Big EDF Storage Deal
Conclusion
For active traders, Tempus AI sits at the intersection of AI hype and hard healthcare execution. TEM’s expanded Bristol Myers Squibb collaboration reinforces that large pharma trusts the Tempus AI data stack to improve trial success in oncology and neuroscience. The LucentAD Alzheimer’s integration and dedicated care‑gap program show Tempus AI methodically entering neurology, turning its Tempus Next platform into a broader clinical utility tool rather than a single‑disease play.
Financially, TEM is still losing money on a GAAP basis, with negative margins and substantial stock‑based compensation. But the trajectory matters. Revenue is climbing from the $1.2B range toward guidance near $1.59B in 2026, while adjusted EBITDA flips positive. The recent $400M 0% convertible notes deal extends the runway for Tempus AI to keep building data assets, refining AI models, and scaling its footprint across oncology, cardiology, and neuropsychiatry.
On the chart, TEM has shown strong upside momentum off the mid‑$40s, with sharp intraday swings that favor disciplined day and swing traders. Liquidity looks solid, volatility is high, and news flow is strong—exactly the mix this community hunts. As Tim Sykes likes to remind traders, “Patterns repeat, but only if you’re prepared to recognize them and disciplined enough to trade them.” As millionaire penny stock trader and teacher Tim Sykes, says, “There is always another play around the corner; don’t chase just because you feel FOMO.”. With Tempus AI, the pattern right now is growth plus volatility. Traders just need a plan and tight risk controls to take advantage of it.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply